FDA Approved: IMATINIB MESYLATE — Original Application (Chartwell RX, LLC)

View source ↗

Summary

FDA approves an original ANDA for imatinib mesylate, granting Chartwell RX, LLC a generic version (ANDA 208429).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Dermatofibrosarcoma Protuberans
• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

ORIG AP for IMATINIB MESYLATE (IMATINIB MESYLATE)